针对瘤治疗的pH响应性抗微生物 melittin模拟-camptothecin结合物的设计
Sujie Huang1,2, Yuxuan Gao1,2, Ling Ma1,2
1Institute of Pharmacology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Asian journal of pharmaceutical sciences
|February 29, 2024
概括
经过pH反应修改的新型梅利丁类型,通过释放坎普托他 (CPT) 和破坏瘤细胞膜,表现出强烈的抗瘤活性. 这些类药物合物为癌症治疗提供了一个有希望的策略,具有降低毒性的毒性.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 梅利丁是一种抗微生物,具有强大的抗瘤特性,但具有高毒性.
- 现有的基于梅利的癌症疗法受到显著副作用的限制.
- 针对性和少毒的抗瘤剂的开发对于有效的癌症治疗至关重要.
研究的目的:
- 设计具有增强pH响应性,细胞透性和膜流动性活动的新型梅利丁类似物.
- 为了制造这些梅利丁类型的坎普托塞辛 (CPT) 结合体,用于向瘤细胞杀死.
- 在临床前模型中评估这些结合物的疗效和毒性.
主要方法:
- 通过用histidine替换 arginine和lysine来合成melittin类似物,以传递pH响应.
- 坎普托西因 (CPT) 与梅利丁类型的C端结合,形成了CPT-AAM-1和CPT-AAM-2.
- 结合物的抗瘤活性和作用机制在模仿瘤微环境的酸性条件下进行了评估.
- 进行了体内研究,以评估CPT-AAM-1在抑制黑色素瘤生长中的有效性.
主要成果:
- 这种新型的梅利丁类同类物体表现出对pH反应,细胞透和膜透的活性.
- 在酸性条件下,CPT-AAM-1和CPT-AAM-2通过CPT释放和膜破坏有效地杀死瘤细胞.
- 梅利丁模拟物在C端的结合证明比N端更有效.
- 在体内,CPT-AAM-1显著抑制了黑色素瘤瘤的生长,毒性可控.
结论:
- 响应pH的抗微生物-药物联合体是开发有效抗瘤剂的可行策略.
- 用histidine修改的melittin类似物为向药物输送和瘤细胞解离提供了一个平台.
- 在这些基于梅利的系统中,C端是适合药物结合的位置.
- 这种方法有望通过提高疗效和减少全身毒性来改善癌症治疗.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


